ASX-listed health stocks continue to be battered by geopolitical and economic headwinds, notes Morgans analyst Scott Power.

According to Future Market Insight, the global diabetic retinopathy market is likely to reach USD 15.50 billion by 2033, registering a CAGR of 5.8%. This is a significant rise from the estimated value ...